Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

How to identify patients with vulnerable plaques.

Virani SS, Ballantyne CM.

Diabetes Obes Metab. 2008 Sep;10(10):824-33. Review.

PMID:
17970757
2.

Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.

Corson MA, Jones PH, Davidson MH.

Am J Cardiol. 2008 Jun 16;101(12A):41F-50F. doi: 10.1016/j.amjcard.2008.04.018. Review.

PMID:
18549871
3.

From carotid plaque biology to serologic markers of vulnerability to predict the risk of cerebrovascular events.

Cola C, Clementi E, Biondi-Zoccai G, Sangiorgi G.

Acta Chir Belg. 2007 Mar-Apr;107(2):129-42. Review.

PMID:
17515260
4.

Comparison of atherosclerotic indicators between cardio ankle vascular index and brachial ankle pulse wave velocity.

Horinaka S, Yabe A, Yagi H, Ishimura K, Hara H, Iemua T, Matsuoka H.

Angiology. 2009 Aug-Sep;60(4):468-76. doi: 10.1177/0003319708325443.

PMID:
19015165
5.

How to identify the asymptomatic high-risk patient?

Schuijf JD, Achenbach S, Zoghbi WA, Boersma E, Raggi P, Weber M, Nagel E, Narula J, Wackers FJ, Poldermans D, Bax JJ.

Curr Probl Cardiol. 2009 Nov;34(11):539-77. doi: 10.1016/j.cpcardiol.2009.07.001. Review.

PMID:
19804855
6.

Novel markers of inflammation in atherosclerosis.

Virani SS, Polsani VR, Nambi V.

Curr Atheroscler Rep. 2008 Apr;10(2):164-70. Review.

PMID:
18417072
7.

Identifying the vulnerable patient with rupture-prone plaque.

Weintraub HS.

Am J Cardiol. 2008 Jun 16;101(12A):3F-10F. doi: 10.1016/j.amjcard.2008.04.013.

PMID:
18549869
8.

The vulnerable patient: refocusing on the plaque?

Eijgelaar WJ, Heeneman S, Daemen MJ.

Thromb Haemost. 2009 Aug;102(2):231-9. doi: 10.1160/TH09-01-0030. Review.

PMID:
19652873
9.

Lp-PLA2: a new kid on the block.

Zalewski A, Nelson JJ, Hegg L, Macphee C.

Clin Chem. 2006 Sep;52(9):1645-50. Review.

10.

Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.

Anderson JL.

Am J Cardiol. 2008 Jun 16;101(12A):23F-33F. doi: 10.1016/j.amjcard.2008.04.015. Review.

PMID:
18549868
11.

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

Mohler ER 3rd, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators..

J Am Coll Cardiol. 2008 Apr 29;51(17):1632-41. doi: 10.1016/j.jacc.2007.11.079.

12.

Extracoronary atherosclerosis in patients with chronic ischemic heart disease: relationship with risk factors and the severity of coronary artery disease.

Pipitone S, Corrado E, Muratori I, Novo G, Evola S, Fabbiano A, Trapani R, Zarcone P, Assennato P, Hoffmann E, Novo S.

Int Angiol. 2007 Dec;26(4):346-52.

PMID:
18091702
13.

Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.

Khakpour H, Frishman WH.

Cardiol Rev. 2009 Sep-Oct;17(5):222-9. doi: 10.1097/CRD.0b013e3181b2434e. Review.

PMID:
19690473
14.

Non-conventional markers of atherosclerosis before and after gastric banding surgery.

Hanusch-Enserer U, Zorn G, Wojta J, Kopp CW, Prager R, Koenig W, Schillinger M, Roden M, Huber K.

Eur Heart J. 2009 Jun;30(12):1516-24. doi: 10.1093/eurheartj/ehp108.

15.

Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease.

Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, Sumida H, Matsui K, Jinnouchi H, Ogawa H.

J Am Coll Cardiol. 2009 Aug 11;54(7):601-8. doi: 10.1016/j.jacc.2009.05.022.

16.

Biomarkers of premature atherosclerosis.

Kampoli AM, Tousoulis D, Antoniades C, Siasos G, Stefanadis C.

Trends Mol Med. 2009 Jul;15(7):323-32. doi: 10.1016/j.molmed.2009.06.001. Review.

PMID:
19577961
17.

Childhood levels of serum apolipoproteins B and A-I predict carotid intima-media thickness and brachial endothelial function in adulthood: the cardiovascular risk in young Finns study.

Juonala M, Viikari JS, Kähönen M, Solakivi T, Helenius H, Jula A, Marniemi J, Taittonen L, Laitinen T, Nikkari T, Raitakari OT.

J Am Coll Cardiol. 2008 Jul 22;52(4):293-9. doi: 10.1016/j.jacc.2008.03.054.

18.

Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.

Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulten LM, Salonen JT, Tuomainen TP, Yki-Järvinen H, Keech AC, Taskinen MR.

J Am Coll Cardiol. 2008 Dec 16;52(25):2190-7. doi: 10.1016/j.jacc.2008.09.049.

19.

Relationship between ankle-brachial index and carotid intima-media thickness in HIV-infected patients.

Gutiérrez F, Bernal E, Padilla S, Hernández I, Masiá M.

AIDS. 2008 Jul 11;22(11):1369-71. doi: 10.1097/QAD.0b013e3282f7cb88.

PMID:
18580617
20.

Role of lipoprotein-associated phospholipase A2 in atherosclerosis.

Lavi S, Herrmann J, Lavi R, McConnell JP, Lerman LO, Lerman A.

Curr Atheroscler Rep. 2008 Jun;10(3):230-5. Review.

PMID:
18489851
Items per page

Supplemental Content

Support Center